Assessment of optimal dosage and biomarker in capecitabine plus fractional cisplatin as the first-line therapy in patients with advanced or recurrent gastric cancer.
Phase of Trial: Phase I
Latest Information Update: 17 May 2016
At a glance
- Drugs Capecitabine (Primary) ; Cisplatin (Primary)
- Indications Gastric cancer
- Focus Adverse reactions; Biomarker
- 04 Jun 2011 New trial record